Enosim Bio-tech Co., Ltd.
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
Breath-Care
Enosim developed the ASTRON, a real-time monitoring and identification breath analysis system for Ventilator-Associated Pneumonia (VAP).
Ventilator-associated pneumonia refers to a bacterial lung infection in intensive care units(ICU), and the patients have been treated with a respirator for more than 48 hours. VAP is the most common nosocomial infection in ICU, and the rate of infection is about 7 to 14%. The mortality rate can reach from 35 to 90%. According to the US study, the additional medical expenses is about US$ 40,000 (about NT$1,280,000). The current species diagnosis relies on the experience of clinical physicians . And the sputum culture to identify bacterium can only get the sucess rate about 60% after 3 to 5 days.
In ICU, there is a umment medical need for the rapid VAP identification. In Taiwan, the number of people in the ICU has increased by 2.4 times in past ten years. However, the patient who leaving rate from respiratory is only 70%, the rate of demanding is reached 142%. The cost as reached NT$4.2 billion.
Enosim developed the ASTRON, a real-time monitoring and identification breath analysis system for Ventilator-Associated Pneumonia (VAP).
Ventilator-associated pneumonia refers to a bacterial lung infection in intensive care units(ICU), and the patients have been treated with a respirator for more than 48 hours. VAP is the most common nosocomial infection in ICU, and the rate of infection is about 7 to 14%. The mortality rate can reach from 35 to 90%. According to the US study, the additional medical expenses is about US$ 40,000 (about NT$1,280,000). The current species diagnosis relies on the experience of clinical physicians . And the sputum culture to identify bacterium can only get the sucess rate about 60% after 3 to 5 days.
In ICU, there is a umment medical need for the rapid VAP identification. In Taiwan, the number of people in the ICU has increased by 2.4 times in past ten years. However, the patient who leaving rate from respiratory is only 70%, the rate of demanding is reached 142%. The cost as reached NT$4.2 billion.
Founded Year
2017
Unified Business No.
56623612
Status
Active
Number of Employees
0
Total Paid-in
Capital
10,015,000 (NT$)
Location of Company
Taiwan
, Hsinchu City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Enosim Bio-Tech Co., Ltd. was spin-off from the e-Nose team of National Tsinghua University. Our team was focus on miniature e-Nose, robust oder identification, IoT, and biomedical applications over 10 years since 2006.
